Description: BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market. The Company’s first product, PURE EP(TM) System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias: Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EP(TM) System in August 2018.
Home Page: www.biosig.com
BSGM Technical Analysis
55 Greens Farms Road
Westport,
CT
06880
United States
Phone:
203 409 5444
Officers
Name | Title |
---|---|
Mr. Kenneth L. Londoner M.B.A., MBA | Founder, CEO & Exec. Chairman |
Mr. Steven Chaussy CPA | Chief Financial Officer |
Mr. John Sieckhaus | Chief Operating Officer |
Dr. Budimir S. Drakulic Ph.D. | Chief Scientist |
Mr. Andrew Gornell Ballou | VP of Investor Relations |
Ms. Brenda Castrodad | VP of HR |
Mr. Gray Fleming Jr. | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Health Care Equipment & Services |
GIC Industry: | Health Care Equipment & Supplies |
GIC Sub-Industry: | Health Care Equipment |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 12.1688 |
Price-to-Sales TTM: | 136.2013 |
IPO Date: | 2014-10-30 |
Fiscal Year End: | December |
Full Time Employees: | 50 |